Enforcement

Penalties, inspection protocols, and recent enforcement actions.

Enforcement is where regulation becomes real: inspection protocols, penalties, recalls, and license actions. Regulators like BfArM, the TGA, and Health Canada conduct site inspections (increasingly remote-first for foreign suppliers), batch audits, and advertising sweeps — and publish outcomes that signal shifting priorities.

For operators, the practical exposures are documentation gaps in the GACP → GMP chain of custody, mislabeled batches, unapproved marketing claims, and late adverse-event reporting. Tracking enforcement actions across jurisdictions reveals where regulators are strict in practice — and where rules exist mainly on paper.

Key considerations

• Inspection cycles include remote assessments and physical site visits
• Penalties scale from warnings to license suspension and product seizure
• Recalls typically trace to labeling, contamination, or spec deviations
• Advertising enforcement is active, especially for wellness claims
• Adverse-event reporting duties apply to license holders, not just manufacturers